CLINIGEN GROUP PLC LS-001
CLINIGEN GROUP PLC LS-001
Action · GB00B89J2419 · A1J440 (XLON)
Aperçu Indicateurs financiers
Pas de cours
n/a

Cours actuels de CLINIGEN GROUP PLC LS-001

BourseTickerDeviseDernier échangeCoursVariation journalière
XLON: London
London
CLIN.L
GBX
24.04.2025 19:47
925,00 GBX
0,00 GBX

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 0,00 % - - - - -

Profil de l'entreprise pour CLINIGEN GROUP PLC LS-001 Action

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Fonds investis

Les fonds suivants ont investi dans : CLINIGEN GROUP PLC LS-001 investi :

Fonds
iShares MSCI UK Small Cap UCITS ETF GBP (Acc)
Vol. en millions
1.081,40
Part (%)
0,18 %

Données de l'entreprise

Nom CLINIGEN GROUP PLC LS-001
Société Clinigen Group plc
Site web https://www.clinigengroup.com
Marché d'origine XLON London
WKN A1J440
ISIN GB00B89J2419
Type de titre Action
Secteur Healthcare
Industrie Medical - Distribution
PDG Mr. Shaun Chilton
Pays Royaume-Uni
Devise GBP
Employés 1,0 T
Adresse Pitcairn House, Crown Square, First Avenue, DE14 2WW STAFFORDSHIRE
Date d'introduction en bourse 2012-09-25
Dividendes de 'CLINIGEN GROUP PLC LS-001'
Date ex-dividende Dividende par action
02.12.2021 5,46 GBX
18.03.2021 2,15 GBX
05.11.2020 5,46 GBX
19.03.2020 2,15 GBX
07.11.2019 4,75 GBX
21.03.2019 1,95 GBX
08.11.2018 3,84 GBX
22.03.2018 1,76 GBX
09.11.2017 3,40 GBX
23.03.2017 1,60 GBX

Symboles boursiers

Nom Symbole
London CLIN.L

Autres actions

Les investisseurs qui détiennent CLINIGEN GROUP PLC LS-001 ont également les actions suivantes dans leur portefeuille :
AIR BERLIN 14/19
AIR BERLIN 14/19 Obligation
LB.HESS.-THR. IHS 18/25
LB.HESS.-THR. IHS 18/25 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025